Aegis Capital Affirms Advaxis (ADXS) at 'Buy'; MedImmune Agreement Could Open Doors to More Licensing
Tweet Send to a Friend
Aegis Capital affirms Advaxis, Inc. (Nasdaq: ADXS) at Buy with a target price of $15 following news that the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE